Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Moderna Inc (NQ: MRNA )

173.83 -0.47 (-0.27%)
Streaming Delayed Price Updated: 3:28 PM EST, Feb 2, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,090,777
Open 173.40
Bid (Size) 173.73 (1)
Ask (Size) 173.89 (1)
Prev. Close 174.30
Today's Range 170.52 - 176.73
52wk Range 115.03 - 217.25
Shares Outstanding 387,000,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
The 7 Most Undervalued Biotech Stocks to Buy in February 2023
Get your hands on the latest medical innovations at a compelling discount with the most undervalued biotech stocks to buy. 
Via InvestorPlace
Moderna to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, February 23, 2023
Via ACCESSWIRE

Performance

YTD
-2.88%
-2.88%
1 Month
-2.88%
-2.88%
3 Month
+16.96%
+16.96%
6 Month
-6.79%
-6.79%
1 Year
+0.63%
+0.63%

More News

Read More
The 7 Most Undervalued Nasdaq Stocks to Buy in February 2023
Via InvestorPlace
Novavax Shares Jumped in January While Others Slipped
Via MarketBeat
Exposures COVID-19 Product Safety
1 Reason to Buy Novavax in 2023 and 2 Reasons to Sell
Via The Motley Fool
Could This RSV News Make Moderna a Hot Buy Again?
Via The Motley Fool
What 10 Analyst Ratings Have To Say About Moderna
Via Benzinga
Here's the Worst Mistake Novavax Investors Can Make in 2023
Via The Motley Fool
This Discount Growth Stock Is a Once-in-a-Decade Buying Opportunity Right Now
Via The Motley Fool
Why BioNTech And Moderna Shares Are Falling After Pfizer News
Via Benzinga
Biden Administration Plans To End COVID-19 Public Health Emergency In May
Via Benzinga
$1,000 Invested In 4 Of The 5 Vaccine Developers Back When WHO Declared COVID-19 An Emergency Yielded Returns
Via Benzinga
The RSV Vaccine Battle Wages On With Moderna Scoring A Win Vs. Pfizer, GSK
Via Investor's Business Daily
Moderna Granted FDA Breakthrough Therapy Designation for mRNA-1345, An Investigational Respiratory Syncytial Virus (RSV) Vaccine Candidate
Via ACCESSWIRE
2 Struggling Stocks to Buy Hand Over Fist in 2023 and 1 to Avoid Like the Plague
Via The Motley Fool
Novavax Jumps After Pledging To Update Its Covid Shot; Pfizer, Moderna Slip
Via Investor's Business Daily
The 3 Best Biotech Stocks Under $1 to Buy for January
Via InvestorPlace
2 Top Biotech Stocks to Buy for the Long Haul
Via The Motley Fool
Mergers and Acquisitions in 2023 Off To A Strong Start
Via MarketBeat
Exposures Product Safety
How Could GSK's RSV Vaccine Change its Valuation?
Via MarketBeat
Exposures Product Safety
Thursday Predictions: 3 Hot Stocks for Tomorrow
Via InvestorPlace
Healthcare Sector Is Lagging As We Enter 2022 Earnings Season
Via Talk Markets
Moderna, Kellogg And 2 Other Stocks Insiders Are Selling
Via Benzinga
COVID, Shmovid: This Could Be the Next Big Growth Story for Moderna Stock
Via The Motley Fool
Stock Market Rally Pulls Back; Microsoft, Google Slash Jobs; Netflix, Goldman, Tesla In Focus: Weekly Review
Via Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.